Kalvista Pharmaceuticals, Inc. (KALV) Stock Price & Analysis
Kalvista Pharmaceuticals, Inc. (KALV) rose 0.00% to USD 26.99 as of June 10, 2026 at 05:31 UTC, according to Nexqual real-time market data.
KALV last closed at USD 26.99; the session ranged USD 26.98–26.99 on volume of 1,536,520 shares. Market capitalization is $1.44B, with a 52-week range of USD 9.83–26.99 (NGM). Source: Nexqual, June 10, 2026 at 05:31 UTC.
Key Statistics (as of June 10, 2026 at 05:31 UTC)
| Price | USD 26.99 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 26.99 |
| Open | USD 26.98 |
| Day Range | USD 26.98 – 26.99 |
| 52-Week Range | USD 9.83 – 26.99 |
| Volume | 1,536,520 shares |
| Market Cap | $1.44B |
| Exchange | NGM |
Technical Analysis (KALV)
Nexqual's technical model rates KALV "BUY" based on 5 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 05:31 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 88.11 (overbought) |
| vs SMA50 | Above (USD 23.69) |
| MACD | 0.87 (positive) |
Analyst Ratings (KALV)
Wall Street analysts rate KALV "None" based on 5 analysts, with a mean price target of USD 28.6 (range USD 27–35), per Nexqual as of June 10, 2026 at 05:31 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 28.6 |
| High Target | USD 35 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 1 / 6 / 0 |
Earnings (KALV)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $48.62M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.43 vs est -0.38 ▼ miss |
| 2025-12-31 | USD 0.94 vs est -0.53 ▲ beat |
| 2025-09-30 | USD -0.92 vs est -1.04 ▲ beat |
| 2024-10-31 | USD -0.91 vs est -0.91 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:31 UTC.
Financials & Fundamentals (KALV)
| Total Revenue | $114.48M |
|---|---|
| Gross Margin | +51.07% |
| Operating Margin | -57.37% |
| Profit Margin | -118.74% |
| Current Ratio | 5.17 |
| Total Cash | $285.03M |
| Total Debt | $284.31M |
Source: Nexqual, June 10, 2026 at 05:31 UTC.
Financial Health Score (KALV)
Nexqual rates Kalvista Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:31 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $285M cash vs $284M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$89M |
| Efficiency | Mixed — No data |
Ownership (KALV)
| Insider Ownership | +1.72% |
|---|---|
| Institutional Ownership | +131.71% |
| Shares Outstanding | 53.24M |
| Float | 38.18M |
| Short % of Float | +14.37% |
Source: Nexqual, June 10, 2026 at 05:31 UTC.
Leadership (KALV)
Kalvista Pharmaceuticals, Inc. is led by Benjamin L. Palleiko (age 59), CEO & Director, per Nexqual as of June 10, 2026 at 05:31 UTC.
| CEO & Director | Benjamin L. Palleiko (age 59) |
|---|---|
| Chief Financial Officer | Brian Piekos (age 50) |
| Chief Operating Officer | Bilal Arif (age 53) |
| Senior Vice President of Corporate Development | Christopher L. Hamblett |
| Senior Vice President of Regulatory Affairs & QA | Rachel M. Morten |
Major Backers & Investors (KALV)
Notable institutional backers of Kalvista Pharmaceuticals, Inc. include Venrock Adviser, LLC, Frazier Life Sciences Management, L.P. , Suvretta Capital Management, LLC, according to Nexqual as of June 10, 2026 at 05:31 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Venrock Adviser, LLC | 12.16% |
| Frazier Life Sciences Management, L.P. | 9.32% |
| Suvretta Capital Management, LLC | 8.96% |
| Tang Capital Management, LLC | 8.59% |
| SilverArc Capital Management, LLC | 5.4% |
| Capital Group | 5.28% |
| SmallCap World Fund Inc | 5.28% |
| Point72 Asset Management, L.P. | 4.01% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.42% |
| State Street | 5.93% |
Source: Nexqual, June 10, 2026 at 05:31 UTC.
From Kalvista Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2025-07-10)
Key Strengths & Strategy (as disclosed to the SEC)
- KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs.
- Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE).
- The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KURA | Kura Oncology, Inc. | USD 8.81 | ▲ 0.8% |
| ANAB | AnaptysBio, Inc. | USD 51.63 | ▲ 2.5% |
| PTGX | Protagonist Therapeutics, Inc. | USD 105.87 | ▲ 8.72% |
| SNDX | Syndax Pharmaceuticals, Inc. | USD 17.69 | ▲ 2.02% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:31 UTC. This page is informational and not investment advice.